nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B3—Methotrexate—lymphatic system cancer	0.219	0.401	CbGbCtD
Valsartan—CYP2C9—Teniposide—lymphatic system cancer	0.129	0.237	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—lymphatic system cancer	0.128	0.234	CbGbCtD
Valsartan—ALB—Methotrexate—lymphatic system cancer	0.07	0.128	CbGbCtD
Valsartan—Myalgia—Fludarabine—lymphatic system cancer	0.00132	0.0029	CcSEcCtD
Valsartan—Haemoglobin—Bleomycin—lymphatic system cancer	0.00131	0.00288	CcSEcCtD
Valsartan—Haemorrhage—Bleomycin—lymphatic system cancer	0.0013	0.00287	CcSEcCtD
Valsartan—Dyspnoea—Teniposide—lymphatic system cancer	0.00128	0.00282	CcSEcCtD
Valsartan—Neutropenia—Vincristine—lymphatic system cancer	0.00127	0.00279	CcSEcCtD
Valsartan—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00126	0.00278	CcSEcCtD
Valsartan—Oedema—Fludarabine—lymphatic system cancer	0.00126	0.00278	CcSEcCtD
Valsartan—Infection—Fludarabine—lymphatic system cancer	0.00125	0.00276	CcSEcCtD
Valsartan—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00125	0.00275	CcSEcCtD
Valsartan—Decreased appetite—Teniposide—lymphatic system cancer	0.00125	0.00275	CcSEcCtD
Valsartan—Renal failure—Carmustine—lymphatic system cancer	0.00124	0.00274	CcSEcCtD
Valsartan—Vomiting—Mechlorethamine—lymphatic system cancer	0.00124	0.00273	CcSEcCtD
Valsartan—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00124	0.00273	CcSEcCtD
Valsartan—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00124	0.00273	CcSEcCtD
Valsartan—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00123	0.00272	CcSEcCtD
Valsartan—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00123	0.00272	CcSEcCtD
Valsartan—Rash—Mechlorethamine—lymphatic system cancer	0.00123	0.0027	CcSEcCtD
Valsartan—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00123	0.0027	CcSEcCtD
Valsartan—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00123	0.0027	CcSEcCtD
Valsartan—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00122	0.00268	CcSEcCtD
Valsartan—Anorexia—Fludarabine—lymphatic system cancer	0.0012	0.00265	CcSEcCtD
Valsartan—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00117	0.00259	CcSEcCtD
Valsartan—Renal failure—Mitoxantrone—lymphatic system cancer	0.00116	0.00255	CcSEcCtD
Valsartan—Nausea—Mechlorethamine—lymphatic system cancer	0.00116	0.00255	CcSEcCtD
Valsartan—Alopecia—Bleomycin—lymphatic system cancer	0.00115	0.00253	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00115	0.00253	CcSEcCtD
Valsartan—Haemoglobin—Carmustine—lymphatic system cancer	0.00114	0.00252	CcSEcCtD
Valsartan—Urticaria—Teniposide—lymphatic system cancer	0.00114	0.00251	CcSEcCtD
Valsartan—Haemorrhage—Carmustine—lymphatic system cancer	0.00114	0.0025	CcSEcCtD
Valsartan—Abdominal pain—Teniposide—lymphatic system cancer	0.00113	0.0025	CcSEcCtD
Valsartan—Paraesthesia—Fludarabine—lymphatic system cancer	0.00113	0.0025	CcSEcCtD
Valsartan—Dyspnoea—Fludarabine—lymphatic system cancer	0.00112	0.00248	CcSEcCtD
Valsartan—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00112	0.00246	CcSEcCtD
Valsartan—Dyspepsia—Fludarabine—lymphatic system cancer	0.00111	0.00245	CcSEcCtD
Valsartan—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00111	0.00244	CcSEcCtD
Valsartan—Sinusitis—Mitoxantrone—lymphatic system cancer	0.0011	0.00243	CcSEcCtD
Valsartan—Decreased appetite—Fludarabine—lymphatic system cancer	0.0011	0.00242	CcSEcCtD
Valsartan—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00109	0.0024	CcSEcCtD
Valsartan—Fatigue—Fludarabine—lymphatic system cancer	0.00109	0.0024	CcSEcCtD
Valsartan—Constipation—Fludarabine—lymphatic system cancer	0.00108	0.00238	CcSEcCtD
Valsartan—Vasculitis—Methotrexate—lymphatic system cancer	0.00107	0.00237	CcSEcCtD
Valsartan—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00107	0.00236	CcSEcCtD
Valsartan—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00107	0.00235	CcSEcCtD
Valsartan—Urethral disorder—Vincristine—lymphatic system cancer	0.00106	0.00234	CcSEcCtD
Valsartan—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00106	0.00234	CcSEcCtD
Valsartan—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00106	0.00233	CcSEcCtD
Valsartan—Hypersensitivity—Teniposide—lymphatic system cancer	0.00106	0.00233	CcSEcCtD
Valsartan—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00106	0.00233	CcSEcCtD
Valsartan—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00106	0.00233	CcSEcCtD
Valsartan—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00105	0.00231	CcSEcCtD
Valsartan—Asthenia—Teniposide—lymphatic system cancer	0.00103	0.00227	CcSEcCtD
Valsartan—Pruritus—Teniposide—lymphatic system cancer	0.00102	0.00224	CcSEcCtD
Valsartan—Cardiac disorder—Vincristine—lymphatic system cancer	0.00101	0.00222	CcSEcCtD
Valsartan—Alopecia—Carmustine—lymphatic system cancer	0.001	0.00221	CcSEcCtD
Valsartan—Mental disorder—Carmustine—lymphatic system cancer	0.000995	0.00219	CcSEcCtD
Valsartan—Malnutrition—Carmustine—lymphatic system cancer	0.000989	0.00218	CcSEcCtD
Valsartan—Cough—Bleomycin—lymphatic system cancer	0.000989	0.00218	CcSEcCtD
Valsartan—Angiopathy—Vincristine—lymphatic system cancer	0.000984	0.00217	CcSEcCtD
Valsartan—Diarrhoea—Teniposide—lymphatic system cancer	0.000982	0.00216	CcSEcCtD
Valsartan—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000977	0.00215	CcSEcCtD
Valsartan—Chest pain—Bleomycin—lymphatic system cancer	0.000964	0.00213	CcSEcCtD
Valsartan—Myalgia—Bleomycin—lymphatic system cancer	0.000964	0.00213	CcSEcCtD
Valsartan—Alopecia—Vincristine—lymphatic system cancer	0.000958	0.00211	CcSEcCtD
Valsartan—Back pain—Carmustine—lymphatic system cancer	0.000956	0.00211	CcSEcCtD
Valsartan—Mental disorder—Vincristine—lymphatic system cancer	0.00095	0.00209	CcSEcCtD
Valsartan—Alopecia—Mitoxantrone—lymphatic system cancer	0.000933	0.00206	CcSEcCtD
Valsartan—Vision blurred—Carmustine—lymphatic system cancer	0.000932	0.00205	CcSEcCtD
Valsartan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000929	0.00205	CcSEcCtD
Valsartan—Oedema—Bleomycin—lymphatic system cancer	0.000925	0.00204	CcSEcCtD
Valsartan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000925	0.00204	CcSEcCtD
Valsartan—Infection—Bleomycin—lymphatic system cancer	0.000918	0.00202	CcSEcCtD
Valsartan—Back pain—Vincristine—lymphatic system cancer	0.000913	0.00201	CcSEcCtD
Valsartan—Vomiting—Teniposide—lymphatic system cancer	0.000912	0.00201	CcSEcCtD
Valsartan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000905	0.002	CcSEcCtD
Valsartan—Asthenia—Fludarabine—lymphatic system cancer	0.000905	0.00199	CcSEcCtD
Valsartan—Rash—Teniposide—lymphatic system cancer	0.000905	0.00199	CcSEcCtD
Valsartan—Dermatitis—Teniposide—lymphatic system cancer	0.000904	0.00199	CcSEcCtD
Valsartan—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.0009	0.00198	CcSEcCtD
Valsartan—Headache—Teniposide—lymphatic system cancer	0.000899	0.00198	CcSEcCtD
Valsartan—Pruritus—Fludarabine—lymphatic system cancer	0.000892	0.00197	CcSEcCtD
Valsartan—Back pain—Mitoxantrone—lymphatic system cancer	0.000889	0.00196	CcSEcCtD
Valsartan—Anorexia—Bleomycin—lymphatic system cancer	0.000881	0.00194	CcSEcCtD
Valsartan—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000866	0.00191	CcSEcCtD
Valsartan—Photosensitivity—Methotrexate—lymphatic system cancer	0.000866	0.00191	CcSEcCtD
Valsartan—Hypotension—Bleomycin—lymphatic system cancer	0.000864	0.0019	CcSEcCtD
Valsartan—Diarrhoea—Fludarabine—lymphatic system cancer	0.000863	0.0019	CcSEcCtD
Valsartan—Nausea—Teniposide—lymphatic system cancer	0.000852	0.00188	CcSEcCtD
Valsartan—Vertigo—Vincristine—lymphatic system cancer	0.000848	0.00187	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000842	0.00186	CcSEcCtD
Valsartan—Myalgia—Carmustine—lymphatic system cancer	0.000842	0.00186	CcSEcCtD
Valsartan—Chest pain—Carmustine—lymphatic system cancer	0.000842	0.00186	CcSEcCtD
Valsartan—Anxiety—Carmustine—lymphatic system cancer	0.000839	0.00185	CcSEcCtD
Valsartan—Paraesthesia—Bleomycin—lymphatic system cancer	0.00083	0.00183	CcSEcCtD
Valsartan—Dyspnoea—Bleomycin—lymphatic system cancer	0.000824	0.00182	CcSEcCtD
Valsartan—Renal failure acute—Methotrexate—lymphatic system cancer	0.000824	0.00182	CcSEcCtD
Valsartan—Oedema—Carmustine—lymphatic system cancer	0.000807	0.00178	CcSEcCtD
Valsartan—Decreased appetite—Bleomycin—lymphatic system cancer	0.000804	0.00177	CcSEcCtD
Valsartan—Myalgia—Vincristine—lymphatic system cancer	0.000804	0.00177	CcSEcCtD
Valsartan—Cough—Mitoxantrone—lymphatic system cancer	0.000802	0.00177	CcSEcCtD
Valsartan—Infection—Carmustine—lymphatic system cancer	0.000802	0.00177	CcSEcCtD
Valsartan—Vomiting—Fludarabine—lymphatic system cancer	0.000802	0.00177	CcSEcCtD
Valsartan—Rash—Fludarabine—lymphatic system cancer	0.000795	0.00175	CcSEcCtD
Valsartan—Dermatitis—Fludarabine—lymphatic system cancer	0.000794	0.00175	CcSEcCtD
Valsartan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00079	0.00174	CcSEcCtD
Valsartan—Headache—Fludarabine—lymphatic system cancer	0.00079	0.00174	CcSEcCtD
Valsartan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000783	0.00173	CcSEcCtD
Valsartan—Chest pain—Mitoxantrone—lymphatic system cancer	0.000783	0.00173	CcSEcCtD
Valsartan—Myalgia—Mitoxantrone—lymphatic system cancer	0.000783	0.00173	CcSEcCtD
Valsartan—Anxiety—Mitoxantrone—lymphatic system cancer	0.00078	0.00172	CcSEcCtD
Valsartan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00077	0.0017	CcSEcCtD
Valsartan—Oedema—Vincristine—lymphatic system cancer	0.00077	0.0017	CcSEcCtD
Valsartan—Anorexia—Carmustine—lymphatic system cancer	0.000769	0.0017	CcSEcCtD
Valsartan—Infection—Vincristine—lymphatic system cancer	0.000765	0.00169	CcSEcCtD
Valsartan—Nervous system disorder—Vincristine—lymphatic system cancer	0.000755	0.00167	CcSEcCtD
Valsartan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000754	0.00166	CcSEcCtD
Valsartan—Hypotension—Carmustine—lymphatic system cancer	0.000754	0.00166	CcSEcCtD
Valsartan—Oedema—Mitoxantrone—lymphatic system cancer	0.00075	0.00165	CcSEcCtD
Valsartan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00075	0.00165	CcSEcCtD
Valsartan—Nausea—Fludarabine—lymphatic system cancer	0.000749	0.00165	CcSEcCtD
Valsartan—Infection—Mitoxantrone—lymphatic system cancer	0.000745	0.00164	CcSEcCtD
Valsartan—Shock—Mitoxantrone—lymphatic system cancer	0.000738	0.00163	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000735	0.00162	CcSEcCtD
Valsartan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000735	0.00162	CcSEcCtD
Valsartan—Urticaria—Bleomycin—lymphatic system cancer	0.000734	0.00162	CcSEcCtD
Valsartan—Anorexia—Vincristine—lymphatic system cancer	0.000734	0.00162	CcSEcCtD
Valsartan—Insomnia—Carmustine—lymphatic system cancer	0.00073	0.00161	CcSEcCtD
Valsartan—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000729	0.00161	CcSEcCtD
Valsartan—Paraesthesia—Carmustine—lymphatic system cancer	0.000725	0.0016	CcSEcCtD
Valsartan—Hypotension—Vincristine—lymphatic system cancer	0.00072	0.00159	CcSEcCtD
Valsartan—Dyspnoea—Carmustine—lymphatic system cancer	0.000719	0.00159	CcSEcCtD
Valsartan—Somnolence—Carmustine—lymphatic system cancer	0.000717	0.00158	CcSEcCtD
Valsartan—Anorexia—Mitoxantrone—lymphatic system cancer	0.000715	0.00158	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000702	0.00155	CcSEcCtD
Valsartan—Decreased appetite—Carmustine—lymphatic system cancer	0.000702	0.00155	CcSEcCtD
Valsartan—Hypotension—Mitoxantrone—lymphatic system cancer	0.000701	0.00155	CcSEcCtD
Valsartan—Insomnia—Vincristine—lymphatic system cancer	0.000697	0.00154	CcSEcCtD
Valsartan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000697	0.00154	CcSEcCtD
Valsartan—Paraesthesia—Vincristine—lymphatic system cancer	0.000692	0.00152	CcSEcCtD
Valsartan—Constipation—Carmustine—lymphatic system cancer	0.00069	0.00152	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000684	0.00151	CcSEcCtD
Valsartan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000681	0.0015	CcSEcCtD
Valsartan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000674	0.00149	CcSEcCtD
Valsartan—Decreased appetite—Vincristine—lymphatic system cancer	0.00067	0.00148	CcSEcCtD
Valsartan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000669	0.00147	CcSEcCtD
Valsartan—Somnolence—Mitoxantrone—lymphatic system cancer	0.000667	0.00147	CcSEcCtD
Valsartan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000665	0.00147	CcSEcCtD
Valsartan—Fatigue—Vincristine—lymphatic system cancer	0.000664	0.00146	CcSEcCtD
Valsartan—Asthenia—Bleomycin—lymphatic system cancer	0.000663	0.00146	CcSEcCtD
Valsartan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00066	0.00146	CcSEcCtD
Valsartan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00066	0.00145	CcSEcCtD
Valsartan—Constipation—Vincristine—lymphatic system cancer	0.000659	0.00145	CcSEcCtD
Valsartan—Pruritus—Bleomycin—lymphatic system cancer	0.000654	0.00144	CcSEcCtD
Valsartan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000652	0.00144	CcSEcCtD
Valsartan—Fatigue—Mitoxantrone—lymphatic system cancer	0.000647	0.00143	CcSEcCtD
Valsartan—Constipation—Mitoxantrone—lymphatic system cancer	0.000642	0.00141	CcSEcCtD
Valsartan—Abdominal pain—Carmustine—lymphatic system cancer	0.000638	0.00141	CcSEcCtD
Valsartan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00063	0.00139	CcSEcCtD
Valsartan—Neutropenia—Methotrexate—lymphatic system cancer	0.000615	0.00135	CcSEcCtD
Valsartan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000613	0.00135	CcSEcCtD
Valsartan—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000611	0.00135	CcSEcCtD
Valsartan—Abdominal pain—Vincristine—lymphatic system cancer	0.000609	0.00134	CcSEcCtD
Valsartan—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000605	0.00133	CcSEcCtD
Valsartan—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.0006	0.00132	CcSEcCtD
Valsartan—Urticaria—Mitoxantrone—lymphatic system cancer	0.000596	0.00131	CcSEcCtD
Valsartan—Hypersensitivity—Carmustine—lymphatic system cancer	0.000595	0.00131	CcSEcCtD
Valsartan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000593	0.00131	CcSEcCtD
Valsartan—Vomiting—Bleomycin—lymphatic system cancer	0.000588	0.0013	CcSEcCtD
Valsartan—Infestation—Methotrexate—lymphatic system cancer	0.000586	0.00129	CcSEcCtD
Valsartan—Infestation NOS—Methotrexate—lymphatic system cancer	0.000586	0.00129	CcSEcCtD
Valsartan—Rash—Bleomycin—lymphatic system cancer	0.000583	0.00128	CcSEcCtD
Valsartan—Dermatitis—Bleomycin—lymphatic system cancer	0.000582	0.00128	CcSEcCtD
Valsartan—Asthenia—Carmustine—lymphatic system cancer	0.000579	0.00128	CcSEcCtD
Valsartan—Renal failure—Methotrexate—lymphatic system cancer	0.000576	0.00127	CcSEcCtD
Valsartan—Hypersensitivity—Vincristine—lymphatic system cancer	0.000568	0.00125	CcSEcCtD
Valsartan—Epistaxis—Methotrexate—lymphatic system cancer	0.000553	0.00122	CcSEcCtD
Valsartan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000553	0.00122	CcSEcCtD
Valsartan—Asthenia—Vincristine—lymphatic system cancer	0.000553	0.00122	CcSEcCtD
Valsartan—Diarrhoea—Carmustine—lymphatic system cancer	0.000552	0.00122	CcSEcCtD
Valsartan—Nausea—Bleomycin—lymphatic system cancer	0.000549	0.00121	CcSEcCtD
Valsartan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000538	0.00119	CcSEcCtD
Valsartan—Dizziness—Carmustine—lymphatic system cancer	0.000534	0.00118	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—lymphatic system cancer	0.000529	0.00117	CcSEcCtD
Valsartan—Diarrhoea—Vincristine—lymphatic system cancer	0.000527	0.00116	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—lymphatic system cancer	0.000526	0.00116	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—lymphatic system cancer	0.000526	0.00116	CcSEcCtD
Valsartan—Pharyngitis—Methotrexate—lymphatic system cancer	0.000522	0.00115	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00052	0.00115	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—lymphatic system cancer	0.000516	0.00114	CcSEcCtD
Valsartan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000513	0.00113	CcSEcCtD
Valsartan—Vomiting—Carmustine—lymphatic system cancer	0.000513	0.00113	CcSEcCtD
Valsartan—Dizziness—Vincristine—lymphatic system cancer	0.000509	0.00112	CcSEcCtD
Valsartan—Rash—Carmustine—lymphatic system cancer	0.000509	0.00112	CcSEcCtD
Valsartan—Dermatitis—Carmustine—lymphatic system cancer	0.000508	0.00112	CcSEcCtD
Valsartan—Headache—Carmustine—lymphatic system cancer	0.000506	0.00111	CcSEcCtD
Valsartan—Vomiting—Vincristine—lymphatic system cancer	0.00049	0.00108	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000488	0.00108	CcSEcCtD
Valsartan—Rash—Vincristine—lymphatic system cancer	0.000486	0.00107	CcSEcCtD
Valsartan—Dermatitis—Vincristine—lymphatic system cancer	0.000485	0.00107	CcSEcCtD
Valsartan—Headache—Vincristine—lymphatic system cancer	0.000483	0.00106	CcSEcCtD
Valsartan—Nausea—Carmustine—lymphatic system cancer	0.000479	0.00106	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—lymphatic system cancer	0.000477	0.00105	CcSEcCtD
Valsartan—Vomiting—Mitoxantrone—lymphatic system cancer	0.000477	0.00105	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—lymphatic system cancer	0.000475	0.00105	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000474	0.00105	CcSEcCtD
Valsartan—Rash—Mitoxantrone—lymphatic system cancer	0.000473	0.00104	CcSEcCtD
Valsartan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000473	0.00104	CcSEcCtD
Valsartan—Headache—Mitoxantrone—lymphatic system cancer	0.00047	0.00104	CcSEcCtD
Valsartan—Alopecia—Methotrexate—lymphatic system cancer	0.000465	0.00102	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—lymphatic system cancer	0.000461	0.00102	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—lymphatic system cancer	0.000458	0.00101	CcSEcCtD
Valsartan—Nausea—Vincristine—lymphatic system cancer	0.000458	0.00101	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—lymphatic system cancer	0.000449	0.000989	CcSEcCtD
Valsartan—Nausea—Mitoxantrone—lymphatic system cancer	0.000446	0.000982	CcSEcCtD
Valsartan—Back pain—Methotrexate—lymphatic system cancer	0.000443	0.000977	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—lymphatic system cancer	0.000432	0.000952	CcSEcCtD
Valsartan—Vertigo—Methotrexate—lymphatic system cancer	0.000411	0.000907	CcSEcCtD
Valsartan—Cough—Methotrexate—lymphatic system cancer	0.0004	0.000881	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—lymphatic system cancer	0.00039	0.00086	CcSEcCtD
Valsartan—Chest pain—Methotrexate—lymphatic system cancer	0.00039	0.00086	CcSEcCtD
Valsartan—Myalgia—Methotrexate—lymphatic system cancer	0.00039	0.00086	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000387	0.000854	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000374	0.000824	CcSEcCtD
Valsartan—Infection—Methotrexate—lymphatic system cancer	0.000371	0.000819	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000367	0.000808	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000366	0.000807	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—lymphatic system cancer	0.000363	0.0008	CcSEcCtD
Valsartan—Anorexia—Methotrexate—lymphatic system cancer	0.000356	0.000785	CcSEcCtD
Valsartan—Hypotension—Methotrexate—lymphatic system cancer	0.000349	0.00077	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000341	0.000751	CcSEcCtD
Valsartan—Insomnia—Methotrexate—lymphatic system cancer	0.000338	0.000745	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—lymphatic system cancer	0.000336	0.00074	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—lymphatic system cancer	0.000333	0.000735	CcSEcCtD
Valsartan—Somnolence—Methotrexate—lymphatic system cancer	0.000332	0.000733	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—lymphatic system cancer	0.000329	0.000725	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—lymphatic system cancer	0.000325	0.000716	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000323	0.000711	CcSEcCtD
Valsartan—Fatigue—Methotrexate—lymphatic system cancer	0.000322	0.00071	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000306	0.000674	CcSEcCtD
Valsartan—Urticaria—Methotrexate—lymphatic system cancer	0.000297	0.000655	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—lymphatic system cancer	0.000295	0.000651	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000275	0.000607	CcSEcCtD
Valsartan—Asthenia—Methotrexate—lymphatic system cancer	0.000268	0.000591	CcSEcCtD
Valsartan—Pruritus—Methotrexate—lymphatic system cancer	0.000264	0.000583	CcSEcCtD
Valsartan—Diarrhoea—Methotrexate—lymphatic system cancer	0.000256	0.000564	CcSEcCtD
Valsartan—Dizziness—Methotrexate—lymphatic system cancer	0.000247	0.000545	CcSEcCtD
Valsartan—Vomiting—Methotrexate—lymphatic system cancer	0.000238	0.000524	CcSEcCtD
Valsartan—Rash—Methotrexate—lymphatic system cancer	0.000236	0.00052	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—lymphatic system cancer	0.000235	0.000519	CcSEcCtD
Valsartan—Headache—Methotrexate—lymphatic system cancer	0.000234	0.000516	CcSEcCtD
Valsartan—Nausea—Methotrexate—lymphatic system cancer	0.000222	0.000489	CcSEcCtD
